HIV 2023/24

A readable book on HIV infection with which physicians can work specifically and practically.

HIV 2023/24

A readable book on HIV infection with which physicians can work specifically and practically.

ORDER THE CURRENT ISSUE!

OR DOWNLOAD HERE AS A PDF!

ORDER THE CURRENT ISSUE!

OR DOWNLOAD HERE AS A PDF!

What to start with? When to switch? How can a failing antiretroviral drug combination be improved? How to treat pregnant women and children, patients with tuberculosis or other AIDS events, with hepatitis coinfections or with HIV-2? What about STDs and PrEP? To answer these and many more questions, HIV physicians need to be constantly updating themselves. “HIV 2023/2024” will help them – with clear-cut recommendations for everyday practice.
The concept of this book was developed in 1991 by Bernd Sebastian Kamps. The idea was to create a book that gives practical help to physicians, but also to members of other professions who deal with people living with HIV. A textbook that is easily readable and can be used in the daily practice of HIV treatment. A book that, despite (unrestricted) support from the pharmaceutical industry, remains independent and is freely available and accessible via a website. We firmly believe that research, knowledge, and expertise in the field of HIV should be shared and accessible to those dedicated to the treatment and care of people living with HIV. Since the first edition in 1991, the book has been updated more than 20 times and has been downloaded by more than 100.000 physicians worldwide.
As in previous years, all chapters of HIV 2023/24 have been thoroughly revised. A new book was urgently needed almost eight years after the last edition. A lot has happened. Not only have COVID-19 and monkeypox (Mpox) been added, but also many new drugs such as bictegravir, doravirine, lenacapavir, or fostemsavir, and long acting and dual therapies. New chapters on parenteral and other routes of ART administration have been created, as well as chapters on prevention (PrEP!), HIV-2, rheumatology, psychiatry, and trans*medicine.

The complete HIV 2023/2024 edition is freely available.
Click here for the free download:
HIV2023/24 full version as pdf

TABLE OF CONTENTS

1. Introduction
The HIV epidemic
Transmission routes
The natural course of HIV infection
Staging of HIV infection
Epidemiology
Summary

2. HIV Testing
Diagnostics basics
Diagnostics for occupational exposure
Practical hints

3. Pathophysiology of HIV Infection

4. Acute HIV Infection

5. ART 2023
5.1. Perspective
5.2. Overview – Classes of antiretrovirals and specific drugs
5.3. ART 2024+: Beyond the horizon
5.4. Goals and principles of therapy
5.5. When to start with ART?
5.6. The optimal first-line therapy
5.7. Management of side effects
5.8. Simplification, de-escalation
5.9. Virological failure
5.10. Salvage therapy
5.11. Treatment interruptions
5.12. Monitoring ART
5.13. Global Access to HIV Treatment

6. Viral Resistance and Tropism
Methods of resistance testing
Interpretation of genotypic resistance profiles
Summary

7. Opportunistic infections (OI)
Pneumocystis pneumonia (PCP)
Cerebral toxoplasmosis
CMV retinitis
Candidiasis
Tuberculosis
Atypical mycobacteriosis (MAC)
Herpes simplex
Herpes zoster
Progressive multifocal leukoencephalopathy
Bacterial pneumonia
Cryptosporidiosis
Cryptococcosis
Salmonella septicemia
Immune Reconstitution Syndrome (IRIS)
Wasting Syndrome
Rare opportunistic infections (OIs)

8. Kaposi’s sarcoma

9. Malignant lymphomas
Systemic non-Hodgkin’s lymphoma (NHL)
Primary CNS lymphoma
Hodgkin’s lymphoma (HL)
Multicentric Castleman disease (MCD)

10. Non-AIDS-defining malignancies
Anal carcinoma
Testicular tumors
Lung cancer

11. HIV and HBV/HCV co-infections
HCV co-infection
HBV co-infection

12. HIV and COVID-19

13. HIV and sexually transmitted diseases
Epidemiology
Syphilis (Lues)
Gonorrhea (gonorrhea)
Chlamydia, lymphogranuloma venereum (LGV)
Genitoanal mycoplasma infections
Chancroid
Granuloma inguinale (donovanosis, granuloma venereum)
Condylomata acuminata (genital warts)
Shigellosis
Mpox

14. Vaccinations
Practical procedures
Vaccinations in detail (selected vaccinations)

15. HIV and travel medicine
Specific risks

16. HIV-2 infection
Antiretroviral therapy for HIV-2 infection

17. HIV and women

18. HIV and gynecology
Gynecological screening
Cycle and menopause
Other infections

19. Pregnancy and HIV
ART before and during pregnancy
HIV drugs during pregnancy
Risk of perinatal HIV infection
Treatment of the newborn

20. Antiretroviral therapy in children
Therapy requirements and practical procedures

21. Checklist: the new patient
Laboratory tests
Further investigations

22. HIV and cardiopulmonary disease
Lung diseases
Medical history
Pulmonary complications and co-morbidities
Cardiovascular diseases

23. HIV and nephrology
The clinic and diagnosis of nephropathy
Routine tests for kidney damage
HIV-associated nephropathy (HIVAN)
Other glomerulonephritides (GN) in HIV
Therapeutic principles in glomerulonephritis
Renal toxicity of drugs
Renal function and PrEP
Dosage of ART in renal failure
OIs and renal insufficiency

24. Organ transplantation in HIV infection

25. HIV-associated thrombocytopenia

26. HIV-associated skin diseases

27. HIV-1-associated neurocognitive disorder (HAND) and HIV-associated
myelopathy
HAND
HIV myelopathy

28. Neuromuscular diseases
Polyneuropathies and polyradiculitis
Myopathies

29. HIV and psychiatric diseases
Depression and other affective disorders
Psychotic disorders
Addictive disorders
Personality disorders
Legal aspects and psychiatric emergencies

30. HIV and rheumatology
Prevalence
Special features

31. Sexuality
Male sexual dysfunction
Chemsex
Trans*Medicine

32. Prevention of HIV infection
Treatment as Prevention (TasP)
Pre-exposure Prophylaxis (PrEP)
Medical prevention, in addition to TasP and PrEP

33. Preventive HIV-1 vaccination: current status

34. Post-exposure prophylaxis (PEP)

35. Drug Profiles
3TC (lamivudine)
Abacavir
Acyclovir
Amphotericin B
Atazanavir
Atovaquone
Atripla®
Azithromycin
AZT (zidovudine)
Bictegravir
Cabotegravir
Cidofovir
Clarithromycin
Clindamycin
Cobicistat
Combivir®
Cotrimoxazole
Dapsone
Darunavir
Daunorubicin (liposomal)
Delstrigo®
Descovy®
Dolutegravir
Doravirine
Dovato®
Doxorubicin (liposomal)
Efavirenz
Elvitegravir
Emtricitabine (FTC)
Epclusa®
Ethambutol
Etravirine
Eviplera® (USA: Complera®)
Fluconazole
Fosamprenavir
Foscarnet
Fostemsavir
Ganciclovir
Genvoya®
Harvoni®
Ibalizumab
Interferon alpha 2a/2b
Isoniazid
Itraconazole
Juluca®
Kivexa® (USA: Epzicom®)
Lenacapavir
Lopinavir
Maraviroc
Maviret®
Nelfinavir
Nevirapine
Odefsey®
Pentamidine
Pyrimethamine
Raltegravir
Rekambys® (US: Cabenuva®)
Ribavirin
Rifabutin
Rifampicin
Rilpivirine
Ritonavir
Saquinavir
Sofosbuvir
Stribild®
Sulfadiazine
Symtuza®
T-20 (enfuvirtide)
Tenofovir-DF (TDF) and Tenofovir-AF (TAF)
Tipranavir
Triumeq®
Trizivir®
Truvada®
Valganciclovir
Vosevi®
Zepatier®

36. Drug interactions
Combinations of ART + ART
ART + concomitant medications
Gastrointestinally active substances
Antiarrhythmics
Antibiotics/tuberculostatics
Antidepressants
Antidiabetics (oral)
Antihelmintics
Antihistamines
Anticoagulants/antiplatelet agents
Anticonvulsants
Antifungals
Calcium antagonists (CCB)
Immunosuppressants/cytostatics
Contraceptives
Malaria/Protozoan Therapy
Phosphodiesterase type 5 inhibitors
Statins/lipid-lowering agents
Substitution
Virustatics/antivirals
Other

37. ART – alternative administrations

This project has been supported with unrestricted grants from:

https://viivexchange.com/de-de/

What to start with? When to switch? How can a failing antiretroviral drug combination be improved? How to treat pregnant women and children, patients with tuberculosis or other AIDS events, with hepatitis coinfections or with HIV-2? What about STDs and PrEP? To answer these and many more questions, HIV physicians need to be constantly updating themselves. “HIV 2023/2024” will help them – with clear-cut recommendations for everyday practice.
The concept of this book was developed in 1991 by Bernd Sebastian Kamps. The idea was to create a book that gives practical help to physicians, but also to members of other professions who deal with people living with HIV. A textbook that is easily readable and can be used in the daily practice of HIV treatment. A book that, despite (unrestricted) support from the pharmaceutical industry, remains independent and is freely available and accessible via a website. We firmly believe that research, knowledge, and expertise in the field of HIV should be shared and accessible to those dedicated to the treatment and care of people living with HIV. Since the first edition in 1991, the book has been updated more than 20 times and has been downloaded by more than 100.000 physicians worldwide.
As in previous years, all chapters of HIV 2023/24 have been thoroughly revised. A new book was urgently needed almost eight years after the last edition. A lot has happened. Not only have COVID-19 and monkeypox (Mpox) been added, but also many new drugs such as bictegravir, doravirine, lenacapavir, or fostemsavir, and long acting and dual therapies. New chapters on parenteral and other routes of ART administration have been created, as well as chapters on prevention (PrEP!), HIV-2, rheumatology, psychiatry, and trans*medicine.
Free download of the new book from the beginning of November. To download the version 2015/16, click here:
HIV2015/16-full version as pdf

TABLE OF CONTENTS

1. Introduction
The HIV epidemic
Transmission routes
The natural course of HIV infection
Staging of HIV infection
Epidemiology
Summary

2. HIV Testing
Diagnostics basics
Diagnostics for occupational exposure
Practical hints

3. Pathophysiology of HIV Infection

4. Acute HIV Infection

5. ART 2023
5.1. Perspective
5.2. Overview – Classes of antiretrovirals and specific drugs
5.3. ART 2024+: Beyond the horizon
5.4. Goals and principles of therapy
5.5. When to start with ART?
5.6. The optimal first-line therapy
5.7. Management of side effects
5.8. Simplification, de-escalation
5.9. Virological failure
5.10. Salvage therapy
5.11. Treatment interruptions
5.12. Monitoring ART
5.13. Global Access to HIV Treatment

6. Viral Resistance and Tropism
Methods of resistance testing
Interpretation of genotypic resistance profiles
Summary

7. Opportunistic infections (OI)
Pneumocystis pneumonia (PCP)
Cerebral toxoplasmosis
CMV retinitis
Candidiasis
Tuberculosis
Atypical mycobacteriosis (MAC)
Herpes simplex
Herpes zoster
Progressive multifocal leukoencephalopathy
Bacterial pneumonia
Cryptosporidiosis
Cryptococcosis
Salmonella septicemia
Immune Reconstitution Syndrome (IRIS)
Wasting Syndrome
Rare opportunistic infections (OIs)

8. Kaposi’s sarcoma

9. Malignant lymphomas
Systemic non-Hodgkin’s lymphoma (NHL)
Primary CNS lymphoma
Hodgkin’s lymphoma (HL)
Multicentric Castleman disease (MCD)

10. Non-AIDS-defining malignancies
Anal carcinoma
Testicular tumors
Lung cancer

11. HIV and HBV/HCV co-infections
HCV co-infection
HBV co-infection

12. HIV and COVID-19

13. HIV and sexually transmitted diseases
Epidemiology
Syphilis (Lues)
Gonorrhea (gonorrhea)
Chlamydia, lymphogranuloma venereum (LGV)
Genitoanal mycoplasma infections
Chancroid
Granuloma inguinale (donovanosis, granuloma venereum)
Condylomata acuminata (genital warts)
Shigellosis
Mpox

14. Vaccinations
Practical procedures
Vaccinations in detail (selected vaccinations)

15. HIV and travel medicine
Specific risks

16. HIV-2 infection
Antiretroviral therapy for HIV-2 infection

17. HIV and women

18. HIV and gynecology
Gynecological screening
Cycle and menopause
Other infections

19. Pregnancy and HIV
ART before and during pregnancy
HIV drugs during pregnancy
Risk of perinatal HIV infection
Treatment of the newborn

20. Antiretroviral therapy in children
Therapy requirements and practical procedures

21. Checklist: the new patient
Laboratory tests
Further investigations

22. HIV and cardiopulmonary disease
Lung diseases
Medical history
Pulmonary complications and co-morbidities
Cardiovascular diseases

23. HIV and nephrology
The clinic and diagnosis of nephropathy
Routine tests for kidney damage
HIV-associated nephropathy (HIVAN)
Other glomerulonephritides (GN) in HIV
Therapeutic principles in glomerulonephritis
Renal toxicity of drugs
Renal function and PrEP
Dosage of ART in renal failure
OIs and renal insufficiency

24. Organ transplantation in HIV infection

25. HIV-associated thrombocytopenia

26. HIV-associated skin diseases

27. HIV-1-associated neurocognitive disorder (HAND) and HIV-associated
myelopathy
HAND
HIV myelopathy

28. Neuromuscular diseases
Polyneuropathies and polyradiculitis
Myopathies

29. HIV and psychiatric diseases
Depression and other affective disorders
Psychotic disorders
Addictive disorders
Personality disorders
Legal aspects and psychiatric emergencies

30. HIV and rheumatology
Prevalence
Special features

31. Sexuality
Male sexual dysfunction
Chemsex
Trans*Medicine

32. Prevention of HIV infection
Treatment as Prevention (TasP)
Pre-exposure Prophylaxis (PrEP)
Medical prevention, in addition to TasP and PrEP

33. Preventive HIV-1 vaccination: current status

34. Post-exposure prophylaxis (PEP)

35. Drug Profiles
3TC (lamivudine)
Abacavir
Acyclovir
Amphotericin B
Atazanavir
Atovaquone
Atripla®
Azithromycin
AZT (zidovudine)
Bictegravir
Cabotegravir
Cidofovir
Clarithromycin
Clindamycin
Cobicistat
Combivir®
Cotrimoxazole
Dapsone
Darunavir
Daunorubicin (liposomal)
Delstrigo®
Descovy®
Dolutegravir
Doravirine
Dovato®
Doxorubicin (liposomal)
Efavirenz
Elvitegravir
Emtricitabine (FTC)
Epclusa®
Ethambutol
Etravirine
Eviplera® (USA: Complera®)
Fluconazole
Fosamprenavir
Foscarnet
Fostemsavir
Ganciclovir
Genvoya®
Harvoni®
Ibalizumab
Interferon alpha 2a/2b
Isoniazid
Itraconazole
Juluca®
Kivexa® (USA: Epzicom®)
Lenacapavir
Lopinavir
Maraviroc
Maviret®
Nelfinavir
Nevirapine
Odefsey®
Pentamidine
Pyrimethamine
Raltegravir
Rekambys® (US: Cabenuva®)
Ribavirin
Rifabutin
Rifampicin
Rilpivirine
Ritonavir
Saquinavir
Sofosbuvir
Stribild®
Sulfadiazine
Symtuza®
T-20 (enfuvirtide)
Tenofovir-DF (TDF) and Tenofovir-AF (TAF)
Tipranavir
Triumeq®
Trizivir®
Truvada®
Valganciclovir
Vosevi®
Zepatier®

36. Drug interactions
Combinations of ART + ART
ART + concomitant medications
Gastrointestinally active substances
Antiarrhythmics
Antibiotics/tuberculostatics
Antidepressants
Antidiabetics (oral)
Antihelmintics
Antihistamines
Anticoagulants/antiplatelet agents
Anticonvulsants
Antifungals
Calcium antagonists (CCB)
Immunosuppressants/cytostatics
Contraceptives
Malaria/Protozoan Therapy
Phosphodiesterase type 5 inhibitors
Statins/lipid-lowering agents
Substitution
Virustatics/antivirals
Other

37. ART – alternative administrations

This project has been supported with unrestricted grants from:

https://viivexchange.com/de-de/

THE EDITORS

Christian Hoffmann, MD, PhD

Hoffmann started his work on HIV/AIDS in 1995 as a research fellow at the Outpatient Clinic of Infectious Diseases, University of Eppendorf, Hamburg. He also worked at the University of Kiel, the Curatorium for Immunodeficiency, Munich and at the ifi institute, Hospital St. Georg, Hamburg. He has been the Editor of HIV Medicine since 2003 and the Scientific Secretary of the Munich AIDS Days since 2002. He has been elected chair of the KAAD (German Clinical AIDS Working Group) 2007-2010 and participated in numerous clinical trials on HIV and AIDS. CH published more than 100 refereed papers, abstracts, and book chapters. His research interests encompass HIV-related malignancies, opportunistic infections and new ARVs. He currently works at the Infektionsmedizinisches Centrum Hamburg which is among the largest HIV centres in Germany.

Jürgen Rockstroh, MD, PhD

Rockstroh is a Professor of Medicine at the University of Bonn and has been Head of an HIV outpatient clinic since 1995. He is an investigator from various HIV studies and has considerable experience with various ARVs and clinical trials for treatment of HIV and hepatitis co-infection. Jürgen Rockstroh’s department treats the world’s largest cohort of HIV-infected haemophiliacs. His research interests encompass antiretroviral therapy, the course of HIV disease in haemophiliacs, HIV/HCV co-infection, and cytokines and apoptosis before and after antiretroviral therapy. JKR is a prolific speaker at international conferences and has published more than 100 articles and book chapters. From 2007-2011, he was the president of the German AIDS Society (DAIG). He is also a member of the Executive Committee of the European AIDS Clinical Society and the Co-Chairman of the 12th European AIDS Conference held in Cologne 2009.

CONTACT  |  ORDER A BOOK

We are always thankful for hints, criticism, corrections and ideas.
The HIV book 2023/24 can be ordered directly from Medizin Fokus Verlag as a hardcopy by mail and prepayment by bank transfer or PayPal (no cash on delivery). The books are usually shipped within 1-3 working days. Please fill out the contact form completely with your address and e-mail address.

Ihre Nachricht wurde gesendet. Vielen Dank!
Fehlermeldung. Bitte versuchen Sie es später noch einmal

ATTENTION:
When paying to the account, please make sure to include your name and delivery address!

Medizin Fokus Verlag
Hamburger Sparkasse
IBAN DE59 2005 0550 1241 1414 21
SWIFT HASPDEHHXXX

Price
€ 48 / each book
€ 42 / book – quantity discount ≥ 5 books
€ 40 / book – quantity discount  ≥ 10 books

Shipping charges:
Germany: included
European Union: € 10 per book
International (Non-EU): € 17 (1-4 books)

CONTACT  |  ORDER A BOOK

We are always thankful for hints, criticism, corrections and ideas.
The HIV book 2023/24 can be ordered directly from Medizin Fokus Verlag as a hardcopy by mail and prepayment by bank transfer or PayPal (no cash on delivery). The books are usually shipped within 1-3 working days. Please fill out the contact form completely with your address and e-mail address.

Ihre Nachricht wurde gesendet. Vielen Dank!
Fehlermeldung. Bitte versuchen Sie es später noch einmal

ATTENTION:
When paying to the account, please make sure to include your name and delivery address!

Medizin Fokus Verlag
Hamburger Sparkasse
IBAN DE59 2005 0550 1241 1414 21
SWIFT HASPDEHHXXX

Price
€ 48 / each book
€ 42 / book – quantity discount ≥ 5 books
€ 40 / book – quantity discount  ≥ 10 books

Shipping charges:
Germany: included
European Union: € 10 per book
International (Non-EU): € 17 (1-4 books)